These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29701129)

  • 21. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.
    Sánchez-Ramos J; Dávila-Fajardo CL; Toledo Frías P; Díaz Villamarín X; Martínez-González LJ; Martínez Huertas S; Burillo Gómez F; Caballero Borrego J; Bautista Pavés A; Marín Guzmán MC; Ramirez Hernández JA; Correa Vilches C; Cabeza Barrera J
    Int J Cardiol; 2016 Dec; 225():289-295. PubMed ID: 27744205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
    Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
    Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
    Empey PE; Stevenson JM; Tuteja S; Weitzel KW; Angiolillo DJ; Beitelshees AL; Coons JC; Duarte JD; Franchi F; Jeng LJB; Johnson JA; Kreutz RP; Limdi NA; Maloney KA; Owusu Obeng A; Peterson JF; Petry N; Pratt VM; Rollini F; Scott SA; Skaar TC; Vesely MR; Stouffer GA; Wilke RA; Cavallari LH; Lee CR;
    Clin Pharmacol Ther; 2018 Oct; 104(4):664-674. PubMed ID: 29280137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Two Point-of-Care
    Zhou Y; Armstead AR; Coshatt GM; Limdi NA; Harada S
    Ann Clin Lab Sci; 2017 Nov; 47(6):738-743. PubMed ID: 29263048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).
    Mikkelsson J; Paana T; Lepantalo A; Karjalainen PP
    Int J Cardiol; 2016 Jan; 202():463-6. PubMed ID: 26436674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
    Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes.
    Chen K; Zhang R; Liu H; Guo X; Li P; Liu X
    Clin Lab; 2016 Sep; 62(9):1773-1780. PubMed ID: 28164572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.
    Tan SSN; Fong AYY; Mejin M; Gerunsin J; Kong KL; Chin FYY; Tiong LL; Lim MSH; Asri S; Khiew NZ; Voon CY; Mohd Amin NH; Cham YL; Koh KT; Oon YY; Ong TK
    Pharmacogenomics; 2017 Aug; 18(13):1225-1239. PubMed ID: 28745576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 36. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI.
    Erathi HV; Durgaprasad R; Velam V; Pvgk S; Rodda M; C K; Kanavath SN
    Minerva Cardioangiol; 2018 Feb; 66(1):16-25. PubMed ID: 28752728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
    Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T
    Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
    Jiang M; You JH
    Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.